Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia

Medical Journal of Australia

Volumn 194, Issue 7, 2011, Pages 369-371

  Richards, Michael ^a   Knox, James ^b,c   Elliott, Briony ^d   Mackin, Kate ^e   Lyras, Dena ^e   Waring, Lynette J ^c   Riley, Thomas V ^f  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c MELBOURNE PATHOLOGY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLAVULANATE POTASSIUM PLUS TICARCILLIN; METRONIDAZOLE; MOXIFLOXACIN; NORADRENALIN; TIMENTIN; VANCOMYCIN;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BLOOD CULTURE; CASE REPORT; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG DOSE INCREASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALE; MORBIDITY; MORTALITY; POLYMERASE CHAIN REACTION; RIBOTYPING; SEPSIS; URINARY TRACT INFECTION;

EID: 79955493719     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2011.tb03012.x     Document Type: Article

References (13)

1. O'Neill GL, Ogunsola FT, Brazier JS, Duerden BI. Modification of a PCRribotyping method for application as a routine typing scheme for Clostridium difficile. Anaerobe 1996; 2: 205-209.
2. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-2449.
3. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-2441.
4. Clements CAA, Soares Magalhães RJ, Tatem AJ, et al. Clostridium difficile polymerase chain reaction ribotype 027: assessing the risks of further global spread. Lancet Infect Dis 2010; 10: 395-404.
5. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084.
6. Pepin J, Saheb N, Coulombe M-A, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a\ cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.
7. Riley TV, Thean S, Hool G, Golledge CL. First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Med J Aust 2009; 190: 706-708.
8. Aksenoka K, Balode A, Grope I, et al. C type=contributor>lostridium difficile associated disease clinical and molecular data. Acta Chirurgica Latviensis 2009; 9: 56-61.
9. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-455.
10. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307.
11. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002; 35: 690-696.
12. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-1172.
13. Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007; 45 Suppl 2: S122-S128.